Palatin Technologies - PTN Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PTN shares.
View PTN analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 1 year target prices for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they expect the company's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 1,893.4% from the stock's current price.
View analysts price targets for PTN or view top-rated stocks among Wall Street analysts.

Palatin Technologies' stock was trading at $3.87 at the beginning of 2023. Since then, PTN shares have decreased by 22.2% and is now trading at $3.01.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023.
View our PTN earnings forecast.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The biopharmaceutical company had revenue of $0.16 million for the quarter. Palatin Technologies had a negative trailing twelve-month return on equity of 169.74% and a negative net margin of 1,713.72%. During the same period in the prior year, the business earned ($0.50) earnings per share.

Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.07%), Geode Capital Management LLC (0.71%), Millennium Management LLC (0.49%), Dimensional Fund Advisors LP (0.19%), Morgan Stanley (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr.
View institutional ownership trends.

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTN stock can currently be purchased for approximately $3.01.

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $28.08 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($3.95) on an earnings per share basis.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202.